80 Results

FDA approves Cyramza for patients with hepatocellular carcinoma with an alpha-fetoprotein

 Added 1 month ago

Eli Lilly and Company announced that the FDA has approved Cyrazma (ramucirumab injection, 10 mg/mL solution), as a single agent,...

Phase III TAPPAS trial of TRC 105 + Votrient terminated in sarcoma

 Added 2 months ago

TRACON Pharmaceuticals announced that its Phase III TAPPAS trial evaluating TRC 105 (carotuximab) in combination with Votrient (pazopanib) in patients...

The Phase III KEYNOTE-240 trial evaluating Keytruda for advanced hepatocellular carcinoma (liver cancer)did not meet its co-primary endpoints.Merck Inc,.

 Added 3 months ago

Merck Inc., announced that the pivotal Phase III KEYNOTE-240 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, plus best supportive care, for...

Phase III REACH-2 study of Cyramza to treat AFP-High liver cancer is published in The Lancet Oncology. - Eli Lilly

 Added 4 months ago

Eli Lilly and Company announced that results from the global Phase III REACH-2 study of Cyramza (ramucirumab) as a single...

FDA approves Cabometyx for hepatocellular carcinoma in patients previously treated with sorafenib.-Exelixis + Ipsen

 Added 4 months ago

Exelixis, Inc. announced that the FDA approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously...

NICE recommends use of Lenvima in liver cancer.- Eisai and Merck Inc.

 Added 5 months ago

The National Institute for Health and Care excellence (NICE) has recommended Lenvima (lenvatinib), from Eisai and Merck Inc., as a...

NICE reverses earlier ruling and recommends use of Stivarga in liver cancer.- Bayer HealthCare.

 Added 6 months ago

The National Institute for Health and Care Excellence (NICE) has recommended the NHS use of Stivarga (regorafenib) from Bayer HealthCare,...

EU approves Cabometyx for liver cancer.- Ipsen + Exelixis.

 Added 7 months ago

Exelixis announced that its partner Ipsen received approval from the European Commission (EC) for Cabometyx (cabozantinib) tablets as a monotherapy...

TAPPAS phase III trial shows ApoStream effective in capturing tumour cells in angiosarcoma.- Precision for Medicine.

 Added 7 months ago

Precision for Medicine and TRACON Pharmaceuticals announced the publication of biomarker results from the TAPPAS phase III clinical trial that...

FDA gives accelerated approval to Keytruda for previously treated hepatocellular carcinoma.- Merck Inc.

 Added 7 months ago

Merck Inc announced that the FDA has approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with hepatocellular...

Load more